TITLE

Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

AUTHOR(S)
Koutouzis, Michael; Lagerqvist, Bo; James, Stefan; Omerovic, Elmir; Matejka, Göran; Grip, Lars; Albertsson, Per
PUB. DATE
September 2011
SOURCE
Heart;Sep2011, Vol. 97 Issue 18, p1484
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Bivalirudin reduces bleeding events and is associated with a lower mortality than the combination of unfractionated heparin (UFH) and glycoprotein IIb/IIIa inhibitor during primary percutaneous coronary intervention (PCI). However, the effect of adding UFH in patients with ST elevation myocardial infarction (STEMI) treated with bivalirudin during primary PCI is unknown. Methods: Patients enrolled in the national Swedish Coronary Angiography and Angioplasty Registry who underwent primary PCI due to STEMI with bivalirudin as anticoagulant were evaluated. Patients were divided into two groups: those treated with bivalirudin only and those treated with bivalirudin plus a bolus dose of UFH. Results: 2996 patients were included in the study: 1928 (64%) received only bivalirudin and 1068 (36%) received bivalirudin plus a bolus dose of UFH. The primary combined endpoint of death or target lesion thrombosis at 30 days occurred more often in the bivalirudin group (11.3% vs 6.5%, OR 0.55, 95% CI 0.41 to 0.72, p<0.001). This difference remained significant after adjustment (HR 0.64, 95% CI 0.44 to 0.95, p¼0.03). Death at 30 days and definite target lesion thrombosis at 30 days did not differ between the two groups after adjustment (9.2% vs 5.1%, adjusted HR 0.66, 95% CI 0.42 to 1.03, p¼0.07 and 2.3% vs 1.5%, adjusted HR 0.59, 95% CI 0.27 to 1.33, p¼0.21, respectively). Conclusion: An additional bolus dose of UFH is associated with a lower rate of death or definite target lesion thrombosis at 30 days in patients undergoing primary PCI with bivalirudin as anticoagulant.
ACCESSION #
65162272

 

Related Articles

  • Long-Term Outcomes with Bare Metal Stents. Boyle, Andrew // Clinical Cardiology Alert;Feb2008, Vol. 27 Issue 2, p11 

    Recently, there has been considerable concern regarding the long-term safety of drug-eluting stents. Reports of late (> 30 days post implantation), and very late (> 1 year post implantation), stent thrombosis have raised concern over these devices, and there has been a corresponding resurgence...

  • ANTICOAGULANT THERAPY TODAY. Vigran, I. Myron // Angiology;Jan1964, Vol. 15 Issue 1, p1 

    A review has been presented of some of the more classical and recent findings in regard to results of anticoagulant therapy in acute myocardial infarction, the long-term prophylactic treatment of coronary artery disease, the use of anticoagulant therapy in cerebral vascular disease, as well as...

  • Bivalirudin superior to heparin in pre-hospital setting for patients with STEMI.  // Cardiology Today;Dec2013, Vol. 16 Issue 12, p16 

    The article discusses findings of a EUROMAX trial indicating better outcomes with ST segment evaluation myocardial infarction (STEMI) anticoagulant bivalirudin in patients who need percutaneous coronary intervention (PCI) as compared to using heparin with or without glycoprotein IIb/IIa inhibitors.

  • Heparin.  // Reactions Weekly;3/14/2009, Issue 1243, p25 

    The article describes a case of thrombocytopenia complicated by thrombosis induced by heparin therapy. A 72-year-old man started receiving heparin after suffering from acute myocardial infarction during coronary bypass. It outlines the symptoms experienced by the patient after three days of...

  • Mitral Stenosis as a Risk Factor for Embolic Myocardial Infarction—Anticoagulation for Some Patients, Individual Treatment for All Liang, Michael; Kelly, Damian; Puri, Aniket; Devlin, Gerard // Heart, Lung & Circulation;Nov2011, Vol. 20 Issue 11, p728 

    A 28 year-old lady with severe rheumatic mitral stenosis presented with non-ST-elevation myocardial infarction secondary to angiographically confirmed right coronary artery embolus with a likely source of mitral valve stenosis origin. This patient was successfully treated medically with dual...

  • Subcutaneous Heparin Compared with Continuous Intravenous Heparin Administration in the Initial Treatment of Deep Vein Thrombosis. Hommes, Daan W.; Bura, Alessandra; Mazzolai, Lucia; Buller, Harry R.; ten Cate, Jan W. // Annals of Internal Medicine;2/15/92, Vol. 116 Issue 4, p279 

    Deals with a study which assessed the efficacy and safety of published randomized trials comparing subcutaneous heparin with continuous intravenous heparin for the initial treatment of deep vein thrombosis. Evidence for the use of heparin as antithrombotic drug; Identification of clinical...

  • Product Management and Efficacy Evaluation of an Anti-Coagulant Enoxaparin (Clexane) in Pakistan. Alam, Shazia; Naqvi, Syed; Gauhar, Shahnaz // Oman Medical Journal;Oct2009, Vol. 24 Issue 4, p264 

    Objective: Enoxaparin (Clexane) is a low molecular weight heparin with a molecular weight of around 4500D. It is a blood thinner used to treat pulmonary embolism, Deep vein thrombosis, unstable angina, non-ST elevated myocardial infarction and ST-segment elevation myocardial infarction. This...

  • Acute Myocardial Infarction Caused by Delayed Heparin-Induced Thrombocytopenia and Acute Immunoreaction due to Re-exposure to Heparin in a Systemic Lupus Erythematosus Patient with HIT Antibodies. Suzuki, Shunji; Sakamoto, Susumu; Okada, Takeaki; Matsuo, Miyako; Saitoh, Atsushi; Matsuo, Takefumi // Clinical & Applied Thrombosis/Hemostasis;Oct2003, Vol. 9 Issue 4, p341 

    A patient with systemic lupus erythematosus and anti-cardiolipin antibodies and antibodies to platelet factor 4/heparin complexes suffered an acute myocardial infarction caused by delayed heparin-induced thrombocytopenia after heparin administration given to treat pulmonary hypertension....

  • COMMENTARY: Fondaparinux reduced death or reinfarction in acute ST-segment elevation myocardial infarction. Borzak, Steven // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p29 

    The article comments on the study related to the use of the drug fondaparinux to treat patients with acute ST-segment elevation myocardial infarction (STEMI). In the study fondaparinux was found useful in reducing death. These trials support the use of anticoagulant therapy in patients with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics